AI assistant
Elicio Therapeutics, Inc. — Director's Dealing 2021
Dec 4, 2021
33784_dirs_2021-12-03_ecb96316-0380-440d-9259-2ab4b8a47602.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Angion Biomedica Corp. (ANGN)
CIK: 0001601485
Period of Report: 2021-12-01
Reporting Person: Goldberg Itzhak (Director, See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-01 | Common Stock | S | 38867 | $3.542 | Disposed | 1831201 | Direct |
| 2021-12-02 | Common Stock | S | 38800 | $3.5136 | Disposed | 1792401 | Direct |
| 2021-12-03 | Common Stock | S | 40215 | $3.3872 | Disposed | 1752186 | Direct |
Footnotes
F1: The shares reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2021 by the Reporting Person
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.31 to $3.79 inclusive.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.36 to $3.64 inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.29 to $3.50 inclusive.